Is There a True Concern Regarding the Use of Hair Dye and Malignancy Development?: A Review of the Epidemiological Evidence Relating Personal Hair Dye Use to the Risk of Malignancy
Many advances in the cosmetic industry have increased our ability to enhance youth and beauty. Hair-coloring products are one such innovation. Over the past several decades, a significant amount of work has been dedicated to understanding the possible long-term side effects associated with hair-dye use, specifically looking at cancer risk. This paper describes the hair-coloring process, highlights the potentially carcinogenic ingredients in various hair-dying products, and reviews the epidemiological evidence relating personal hair-dye use to the risk of developing several types of malignancies.
Comparison of allergEAZE Allergens to Chemotechnique Diagnostics Allergens in the Evaluation of Contact Allergy
An update on the presence of psychiatric comorbidities in acne patients, Part 2: Depression, anxiety, and suicide
Acne vulgaris (AV) is a chronic inflammatory skin disease that affects millions of people. Psychologic disorders such as depression, anxiety, and body dysmorphic disorder are common in patients with AV and the reported prevalence of suicidal ideation and suicide completion in acne patients also is remarkable. Part 1 of this series provided an overview of the prevalence of psychologic disorders in patients with AV Part 2 reviews depression, anxiety, body dysmorphic disorder, and suicidal ideation and completion seen in AV patients. Treatments available for acne patients with coexisting psychiatric illness also are discussed, along with the relationship between oral isotretinoin and depression and suicide.
An update on the presence of psychiatric comorbidities in acne patients, part 1: overview of prevalence
Acne vulgaris (AV) is a chronic inflammatory skin disease that affects millions of people. Psychologic disorders such as depression, anxiety, and body dysmorphic disorder (BDD) are common in patients with AV This article in a 2-part series provides a review of the rates of general psychologic comorbidity, depression, anxiety, and BDD.
The frequency of self-skin examination and full body skin examination in dermatologists
Purpose: Mortalities due to skin cancer are escalating, but early detection via skin examinations can be beneficial. To date, dermatologists have not been isolated as a high-risk population for developing skin cancer, although some evidence suggests that they are a high-risk group. Therefore, the specific aims of this study were to measure the frequency at which dermatologists perform self-skin examination and receive full-body skin examination. Patients and methods: A sample of 476 respondents provided data for this cross-sectional, nine-item survey, which was e-mailed to all registered members in the American Society for Dermatologic Surgery. The initial invitation was sent in the summer of 2007, with reminders sent at four and eight weeks. E-mails contained a unique identifier, and each member could only respond once to the survey sent to that particular e-mail address. Results: 71.7 percent of the respondents reported that they routinely gave themselves a self-skin examination, 25.4 percent reported a monthly exam, 24.5 percent every six months, 17.2 percent once per year, and 4.6 percent every five years. Performing a self-skin examination was not related to age, gender, or history of skin malignancy. Seventy-six percent of all respondents never had a full-body skin examination conducted by another dermatologist, which persisted when analyzed by age (p = 0.0490) and gender (p = 0.0184). Conclusion: Dermatologists are more likely to perform self-skin examination rather than visit another dermatologist for a full-body skin examination
Contact leukoderma from para-phenylenediamine
Interstitial granulomatous dermatitis [Case Report]
A 59-year-old woman with arthritis presented to the Skin Institute of New York with a 2-month history of asymptomatic, small, skin-colored papules that erupted symmetrically on the chest, back, and proximal extremities. Histopathologic examination of a biopsy specimen showed findings of interstitial granulomatous dermatitis. Clinical correlation suggested a diagnosis of interstitial granulomatous dermatitis with arthritis. No change in the lesions resulted from application of clobetasol 0.05 percent ointment to the affected areas
Use of the North American Contact Dermatitis Group Standard 65-allergen series alone in the evaluation of allergic contact dermatitis: a series of 794 patients
BACKGROUND: The 'gold standard' for diagnosing allergic contact dermatitis is patch testing. Previous studies have not adequately addressed the validity and usefulness of the North American Contact Dermatitis Group (NACDG) Standard 65-allergen series alone as a screening tool in the evaluation of contact dermatitis. OBJECTIVE: The purpose of this study is to examine the usefulness of the NACDG series of 65 allergens as an exclusive screening method in the diagnosis of contact allergy. METHODS: A retrospective chart review of 794 patients referred for patch testing with the NACDG Screening Series with or without additional allergens was performed to determine the number of positive patch-test results. The study groups were analyzed to identify whether the positive reactions were to allergens in the NACDG Standard Series or to allergens in the supplementary group. RESULTS: Of the 794 patients patch-tested between July 1, 2004, and July 1, 2006, 590 (74.31%) had a positive reaction to either an NACDG patch-tested allergen or a supplemental allergen; 386 (65.42%) patients testing positive for an allergen were positive to an NACDG allergen only, and 534 (90.51%) of the total positive reactors were positive for at least one NACDG test allergen. CONCLUSION: As a screening tool, the NACDG Standard Series is substantially more efficacious than are more limited standard series when used exclusively in the evaluation of patients with allergic contact dermatitis. More extensive testing, including testing with suspected supplementary allergens determined by thorough history and physical examination, can improve upon the NACDG series as a means to investigate the full causes of contact dermatitis in any individual patient
Allergic contact dermatitis to pimecrolimus [Case Report]
Pimecrolimus suppresses the proinflammatory cytokine production of cutaneous T and mast cells (1). It is used to treat atopic dermatitis and is the active ingredient in the topical formulation pimecrolimus 1.0% cream (Elidel, Novartis Pharma AG, Basel, Switzerland)